Chimeric VLPs production

Immunotherapy is proving to be an effective treatment option for a variety of autoimmunologic diseases. Modulating the immune system to specifically target specific biomarkers and cells while preserving healthy cells is a very promising technique for safer medicines and better patient survival. Dieseases-associated antigens are ideal targets for therapy since they are only expressed by affected cells . Virus-like particles (VLPs), which are safe and potent delivery methods, have the ability to activate the immune system. Vaccines based on VLPs have evolved substantially over the last few decades and have shown considerable promise in preventing autoimmunilogic diseases. The immunogenicity of engineered VLPs as a basis for the creation of effective therapeutic vaccines has been extensively researched. NanoExpo created three platforms that offer numerous copies of disease-associated antigens and other epitopes as a potentially useful tool for future immunotherapy.